BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/29/2016 3:29:00 PM | Browse: 1134 | Download: 2108
 |
Received |
|
2015-08-29 16:59 |
 |
Peer-Review Started |
|
2015-09-01 09:52 |
 |
To Make the First Decision |
|
2015-09-29 12:43 |
 |
Return for Revision |
|
2015-10-08 17:29 |
 |
Revised |
|
2015-11-02 21:28 |
 |
Second Decision |
|
2016-01-06 11:38 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2016-01-18 10:21 |
 |
Articles in Press |
|
2016-01-18 10:21 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2016-03-02 09:19 |
 |
Typeset the Manuscript |
|
2016-03-15 10:45 |
 |
Publish the Manuscript Online |
|
2016-03-29 15:29 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Medicine, Research & Experimental |
Manuscript Type |
Basic Study |
Article Title |
Evaluation of therapeutic effectiveness of 131I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Wei Li, Yan-Hui Ji, Cheng-Xia Li, Zhong-Yun Liu, Ning Li, Lei Fang, Jin Chang and Jian Tan |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
National Natural Science Foundation of China |
81301244 (to Li W) |
National Key Clinical Specialty Project |
|
|
Corresponding Author |
Jian Tan, MD, Professor of Medicine, Chief, Department of Nuclear Medicine, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China. tanpost@163.com |
Key Words |
Radioiodine therapy; Colorectal cancer; Liposome; Epidermal growth factor receptor; Mouse |
Core Tip |
This paper describes liposomes that were assessed for EGFR-targeted binding and cellular uptake in EGFR-overexpressing LS180 colorectal cancer cells and a mouse model of colorectal cancer. Anti-EGFR and non-targeted liposomes were labeled with 131I using the chloramine-T method. The time-dependent cellular uptake of 131I-antiEGFR-BSA-PCL and 131I-BSA-PCL demonstrated the slow-release effects of nanoparticles. The results of confocal microscopic analysis revealed the significant uptake of antiEGFR-BSA-PCL in LS180 cells. This study also investigated the biological effects of internal irradiation and the therapeutic efficacy of 131I-antiEGFR-BSA-PCL on colorectal cancer in a BALB/c mouse model. To address this issue, tumor size, body weight, histopathology, and SPECT imaging were monitored for 33 d post-therapy. The 131I-antiEGFR-BSA-PCL was demonstrated to be superior in regard to cellular binding and uptake compared with control BSA-PCL in the mouse model. |
Publish Date |
2016-03-29 15:29 |
Citation |
Li W, Ji YH, Li CX, Liu ZY, Li N, Fang L, Chang J, Tan J. Evaluation of therapeutic effectiveness of 131I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer. World J Gastroenterol 2016; 22(14): 3758-3768 |
URL |
http://www.wjgnet.com/1007-9327/full/v22/i14/3758.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v22.i14.3758 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345